Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif

Journal of Medicinal Chemistry

Volumn 56, Issue 4, 2013, Pages 1772-1776

  Wagner, Florence F ^a   Olson, David E ^a   Gale, Jennifer P ^a   Kaya, Taner ^a   Weïwer, Michel ^a   Aidoud, Nadia ^a   Thomas, Méryl ^a   Davoine, Emeline L ^a   Lemercier, Bérénice C ^a   Zhang, Yan Ling ^a   Holson, Edward B ^a  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHYLENE DERIVATIVE; HISTONE DEACETYLASE 6; HYDROXAMIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE;

ACETYLATION; ARTICLE; CONCENTRATION RESPONSE; ENZYME ANALYSIS; ENZYME BINDING; ENZYME INHIBITION; ENZYME STRUCTURE; LIGAND BINDING; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 84874638204     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301355j     Document Type: Article

References (49)

1. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nature Rev. Cancer 2006, 6, 38-51 (Pubitemid 43054973)
2. Haberland, M.; Montgomery, R. L.; Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy Nature Rev. Genet. 2009, 10, 32-42
3. Fass, D. M.; Kemp, M. M.; Schroeder, F. A.; Wagner, F. F.; Wang, Q.; Holson, E. B. Histone Acetylation and Deacetylation. In Epigenetic Regulation and Epigenomics: Advances in Molecular Biology and Medicine; (Wiley-VCH Vrlag & Co. KGaA: Weinheim, 2012; pp 515-561.
4. Marks, P. A.; Richon, V. M.; Miller, T.; Kelly, W. K. Histone Deacetylase Inhibitors Adv. Can. Res. 2004, 91, 137-168 (Pubitemid 39140958)
5. de Ruijter, A. J. M.; Van Gennip, A. H.; Caron, H. N.; Kemp, S.; Van Kuilenburg, A. B. P. Histone deacetylases (HDACs): characterization of the classical HDAC family Biochem. J. 2003, 370, 737-749 (Pubitemid 36399066)
6. Glaser, K. B.; Staver, M. J.; Waring, J. F.; Stender, J.; Ulrich, R. G.; Davidsen, S. K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol. Cancer Ther. 2003, 2, 151-163
7. Spange, S.; Wagner, T.; Heinzel, T.; Krämer, O. H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels Int. J. Biochem. Cell Biol. 2009, 41, 185-198
8. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors Nature Rev. Drug Discovery 2006, 5, 769-784 (Pubitemid 44348499)
9. Khan, O.; La Thangue, N. B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications Immunol. Cell Biol. 2012, 90, 85-94
10. Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009, 277, 8-21
11. Chuang, D. M.; Leng, Y.; Marinova, Z.; Kim, H. J.; Chiu, C. T. Multiple roles of HDAC inhibition in neurodegenerative conditions Trends Neurosci. 2009, 32, 591-601
12. Gray, S. G. Epigenetic treatment of neurological disease Epigenomics 2011, 3, 431-450
13. Grayson, D. R.; Kundakovic, M.; Sharma, R. P. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol. Pharmacol. 2010, 77, 126-135
14. Beurel, E. HDAC6 regulates LPS-tolerance in astrocytes PLoS One 2011, 6, e25804
15. McQuown, S. C.; Barrett, R. M.; Matheos, D. P.; Post, R. J.; Rogge, G. A.; Alenghat, T.; Mullican, S. E.; Jones, S.; Rusche, J. R.; Lazar, M. A.; Wood, M. A. HDAC3 is a critical negative regulator of long-term memory formation J. Neurosci. 2011, 31, 764-774
16. Guan, J.-S.; Haggarty, S. J.; Giacometti, E.; Dannenberg, J.-H.; Joseph, N.; Gao, J.; Nieland, T. J. F.; Zhou, Y.; Wang, X.; Mazitschek, R.; Bradner, J. E.; DePinho, R. A.; Jaenisch, R.; Tsai, L.-H. HDAC2 negatively regulates memory formation and synaptic plasticity Nature 2009, 459, 55-60
17. Feng, D.; Liu, T.; Sun, Z.; Bugge, A.; Mullican, S. E.; Alenghat, T.; Liu, X. S.; Lazar, M. A. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism Science 2011, 331, 1315-1319
18. Gluckman, P. D.; Hanson, M. A.; Buklijas, T.; Low, F. M.; Beedle, A. S. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases Nature Rev. Endocrinol. 2009, 5, 401-408
19. Mihaylova, M. M.; Vasquez, D. S.; Ravnskjaer, K.; Denechaud, P.-D.; Yu, R. T.; Alvarez, J. G.; Downes, M.; Evans, R. M.; Montminy, M.; Shaw, R. J. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis Cell 2011, 145, 607-621
20. Chou, D. H.; Holson, E. B.; Wagner, F. F.; Tang, A. J.; Maglathlin, R. L.; Lewis, T. A.; Schreiber, S. L.; Wagner, B. K. Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis Chem Biol. 2012, 19, 669-673
21. Rotilli, D.; Simonetti, G.; Savarino, A.; Palamara, A. T.; Migliaccio, A. R.; Mai, A. Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies Curr. Top. Med. Chem. 2009, 9, 272-291
22. Andrews, K. T.; Haque, A.; Jones, M. K. HDAC inhibitors in parasitic diseases Immunol. Cell Biol. 2012, 90, 66-77
23. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.-F.; Yao, T.-P. HDAC6 is a microtubule-associated deacetylase Nature 2002, 417, 455-458 (Pubitemid 34563539)
24. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo EMBO J. 2003, 22, 1168-1179 (Pubitemid 36313600)
25. Zou, H.; Wu, Y.; Navre, M.; Sang, B.-C. Characterization of the two catalytic domains in histone deacetylase 6 Biochem. Biophys. Res. Commun. 2006, 341, 45-50 (Pubitemid 43117384)
26. Zhang, Y.; Gilquin, B.; Khochbin, S.; Matthias, P. Two catalytic domains are required for protein deacetylation J. Biol. Chem. 2006, 281, 2401-2404 (Pubitemid 43845699)
27. Dompierre, J. P.; Godin, J. D.; Charrin, B. C.; Cordelieres, F. P.; King, S. J. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation J. Neurosci. 2007, 27, 3571-3583 (Pubitemid 46515140)
28. Chen, S.; Owens, G. C.; Makarenkova, H.; Edelman, D. B. HDAC6 regulates mitochondrial transport in hippocampal neurons PLoS One 2010, 5, e10848
29. Rivieccio, A.; Brochier, C.; Willis, D.; Walker, D. E.; D'Annibale, M. A.; McLaughlin, K.; Siddiq, A.; Kosikowski, A. P.; Jaffrey, S. R.; Twiss, J. L.; Ratan, R. R.; Langley, B. HDAC6 is a target for protection and regeneration following injury in the nervous system Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 19599-19604
30. Butler, K. V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kosikowski, A. P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A J. Am. Chem. Soc. 2010, 132, 10842-10846
31. Abad-Zapatero, C.; Metz, J. T. Ligand efficiency indices as guideposts for drug discovery Drug Discovery Today 2005, 10, 464-469
32. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 9997-10002 (Pubitemid 29422500)
33. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431 (Pubitemid 38510559)
34. Reynolds, C. H.; Bembenek, S. D.; Tounge, B. A. The role of molecular size in ligand efficiency Bioorg. Med. Chem. Lett. 2007, 17, 4258-4261 (Pubitemid 47028600)
35. Butler, K. V.; Kozikowski, A. P. Chemical origins of isoform selectivity in histone deacetylase inhibitors Curr. Pharm. Des. 2008, 14, 505-528 (Pubitemid 351516876)
36. Bieliauskas, A. V.; Pflum, M. K. H. Isoform-selective histone deacetylase inhibitors Chem. Soc. Rev. 2008, 37, 1402-1413
37. Estiu, G.; Greenberg, E.; Harrison, C. B.; Kwiatkowski, N. P.; Mazitschek, R.; Bradner, J. E.; Wiest, O. On the structural origin of selectivity in class II selective histone deacetylase Inhibitors J. Med. Chem. 2008, 51, 2898-2906 (Pubitemid 351706018)
38. Santo, L.; Hideshima, T.; Kung, A. L.; Tseng, J.-C.; Tamang, D.; Yang, M.; Jarpe, M.; van Duzer, J. H.; Mazitschek, R.; Ogier, W. C.; Cirstea, D.; Rodig, S.; Eda, H.; Scullen, T.; Canavese, M.; Bradner, J.; Anderson, K. C.; Jones, S. S.; Raje, N. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Blood 2012, 11, 2579-2589
39. Suzuki, T. Explorative study on isoform-selective histone deacetylase inhibitors Chem. Pharm. Bull. 2009, 57, 897-906
40. Dallavalle, S.; Pisano, C.; Zunino, F. Development and therapeutic impact of HDAC6-selective inhibitors Biochem. Pharmacol. 2012, 6, 759-765
41. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 4389-4394 (Pubitemid 36457739)
42. Auzzas, L.; Larsson, A.; Matera, R.; Baraldi, A.; Descheînes- Simard, B.; Giannini, G.; Cabri, W.; Battistuzzi, G.; Gallo, G.; Ciacci, A.; Vesci, L.; Pisano, C.; Hanessian, S. Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity J. Med. Chem. 2010, 53, 8387-8399
43. KrennHrubec, K.; Marshall, B. L.; Hedglin, M.; Verdin, E.; Ulrich, S. M. Design and evaluation of "linkerless" hydroxamic acids as selective HDAC8 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 2874-2878 (Pubitemid 46636249)
44. Smil, D. V.; Manku, S.; Chantigny, Y. A.; Leit, S.; Wahhab, A.; Yan, T. P.; Fournel, M.; Maroun, C.; Li, Z.; Lemieux, A.-M.; Nicolescu, A.; Rahil, J.; Lefebvre, S.; Panetta, A.; Besterman, J. M.; Déziel, R. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 688-692
45. Mazitscheck, R.; Bradner, J. E.; Grachan, M. Histone deacetylase inhibitors and methods of use thereof. PCT US2012/024868, Feb 2, 2012.
46. Holson, E.; Wagner, F.; Weïwer, M.; Zhang, Y. L.; Haggarty, S. H.; Tsai, L. H. Inhibitors of histone deacetylases. WO2012149540 (A1), Nov 1, 2012.
47. Wilson, A. J.; Holson, E.; Wagner, F.; Zhang, Y.-L.; Fass, D. M.; Haggarty, S. J.; Bhaskara, S.; Hiebert, S. W.; Schreiber, S. L.; Khabele, D. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells Cancer Biol. Ther. 2011, 12, 484-493
48. Thaler, F.; Colombo, A.; Mai, A.; Amici, R.; Bigogno, C.; Boggio, R.; Cappa, A.; Carrara, S.; Cataudella, T.; Fusar, F.; Gianti, E.; Joppolo di Ventimiglia, S.; Moroni, M.; Munari, D.; Pain, F.; Regalia, N.; Sartori, L.; Vultaggio, S.; Dondio, G.; Gagliardi, S.; Minucci, S.; Mercurio, C.; Varasi, M. Synthesis and biological evaluation of N -hydroxyphenylacrylamides and N -hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors J. Med. Chem. 2010, 53, 822-839
49. Siliphaivanh, P.; Harrington, P.; Witter, D. J.; Otte, K.; Tempest, P.; Kattar, S.; Kral, A. M.; Fleming, J. C.; Deshmukh, S. V.; Harsch, A.; Secrist, P. J.; Millera, T. A. Design of novel histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 4619-4624 (Pubitemid 47058936)